Burning Rock Biotech Ltd (BNR) ADR EACH REPR 1 ORD SHS SPON
$0.02925
(3.56%)
- Add to watchlist
- This stock can be held in a
$0.02925
(3.56%)
$0.02925
(3.56%)
Business summary
Burning Rock Biotech Ltd is a holding company mainly engaged in the next generation sequencing (NGS) based cancer therapy selection. The Company operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The Company mainly conducts its businesses in the China market.
Contact details
Important dates
General stock information
- Short code:
- BNR
- ISIN:
- US12233L1070
- Market cap:
- $84.28 million
- Shares in issue:
- 102.68 million
- Sector:
- Biotechnology
- Exchange:
- NASDAQ
- Country:
- Cayman Islands
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.